#Shanghai #USA #ADC #Series A #Allink Bio

Allink Biotherapeutics Secures $47 Million Series A Funding

Allink Biotherapeutics, Inc. (AllinkBio), a clinical-stage biotechnology company focusing on advanced antibody-drug conjugates (ADCs) and multispecific antibody therapeutics, recently announced a successful funding round, raising $47 million during its Series A extension. The round was led by Legend Capital alongside Meituan Long-Z Investment, with robust support from various existing and new investors, including Lanchi Ventures, Yuanbio Venture Capital, 5Y Capital, Lapam Capital, and Runzhang Venture Capital.

This funding is essential for the continued global development of two competitive ADC programs currently in Phase I clinical trials. These programs are designed to overcome significant limitations faced by existing biological therapeutics, thereby providing superior treatment options.

Accelerating Clinical Development

The Series A funding will facilitate the advancement of AllinkBio's lead projects: ALK201 and ALK202. ALK201 is an FGFR2b-targeted ADC that has shown promising effectiveness across various tumor types, coupled with a favorable safety profile, making it a potential cornerstone therapy for solid tumors overexpressing FGFR2b. On the other hand, ALK202 is a bispecific ADC targeting EGFR/cMET, showing preliminary clinical evidence as a foundational therapy for non-small cell lung cancer. The program for ALK202 will also expand to evaluate a broader array of biomarker-defined tumor types and patient demographics.

AllinkBio has initiated its clinical development journey for both lead assets utilizing a biomarker-oriented strategy that aims to demonstrate efficacy across a wide spectrum of solid tumors. The company plans to commence combination studies shortly, exploring the therapeutic potential of both candidates in diverse patient populations. These approaches are pivotal for expediting preparations for regulatory approval studies while distinguishing their profiles in respective indications.

Expanding Novel Technology Platforms

In addition to its ADC technology, AllinkBio is establishing a unique platform for masked T-cell engagers (TCEs), furthering the application of TCEs in solid tumors. The company is also advancing a portfolio of best-in-class bi- and multispecific antibody candidates in the immunology sector. These programs are anchored in rational biological principles, aiming to deliver next-generation solutions for underserved patient populations.

Dr. Hui Feng, Founder and CEO of AllinkBio, expressed gratitude for the unwavering support from their investors within such a short timeframe. He stated, “With this backing, we can pursue our clear clinical roadmap to accelerate our lead programs. Besides the two focal programs, our research platform is fully activated and ready to generate innovative drug candidates that will create significant value in the near future.”

Tan Hong, Managing Director at Legend Capital, confirmed that their continued support stems from confidence in AllinkBio's efficient execution and solid development strategy. He remarked, “The rapid clinical advances of their two competitive lead products already affirm the power of AllinkBio's ADC platform, demonstrating substantial added value.”

Xuejing Guo, Managing Director and Head of Healthcare at Meituan Long-Z Investment, shared his enthusiasm for the potential of AllinkBio's technology platform. He noted, “We are deeply impressed by the potential of their technology platform and look forward to supporting the team in translating these original innovations into life-changing therapies for patients worldwide.”

About Allink Biotherapeutics

Founded in 2023, Allink Biotherapeutics is a clinical-stage biotechnology enterprise committed to researching and developing differentiated ADCs and multispecific antibodies for oncology and immunology. Leveraging synergies from innovative platform capabilities and exceptional R&D efficiency, the company has swiftly advanced two ADC candidates into global Phase I clinical trials. AllinkBio is dedicated to enhancing ADC and multispecific antibody development to improve the lives of patients in critical need across the globe.